Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Be3c6f7c9e39a468fec67649c8b5a677b> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Be3c6f7c9e39a468fec67649c8b5a677b NCIT_P378 "NCI" @default.
- Be3c6f7c9e39a468fec67649c8b5a677b type Axiom @default.
- Be3c6f7c9e39a468fec67649c8b5a677b annotatedProperty IAO_0000115 @default.
- Be3c6f7c9e39a468fec67649c8b5a677b annotatedSource NCIT_C158602 @default.
- Be3c6f7c9e39a468fec67649c8b5a677b annotatedTarget "A preparation of human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) gene coupled to the signaling domains from CD28, 4-1BB (CD137) and CD3 zeta, and modified to express the cytokine interleukin-12 (IL-12), with potential immunostimulatory and antineoplastic activities. Upon administration, the anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes target and bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFNg), activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death for the EGFR-overexpressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance." @default.